Sapio SciencesScientistsTM laboratory computing platform, today announced the launch of its new multimodal registration possibilities. This new functionality unifies small molecule, large molecule and multimodal molecule discovery workflows, including entity registration, into a single platform.
With these latest features, Sapio helps R&D teams overcome the collaboration and efficiency challenges traditionally associated with developing multimodal therapies and products.
New methods, such as recombinant proteins, peptides and engineered antibodies, are key drivers of growth in the biopharmaceutical industry. According to BCGrevenue from new technology products has increased by $60 billion in recent years, while revenue from conventional products has decreased by $10 billion.
In addition, BCG predicts that the percentage value of new amendments in the five-year forward pipeline between 2019 and 2023 will increase from 41% to 56%, far outpacing conventional ones.
“The days of viewing drug discovery through the separate lenses of small molecules and large molecules are over,” said Kevin Cramer, president and CEO of Sapio Sciences. “Today, drug discovery in biopharma is increasingly multimodal, and cutting-edge laboratories require a single unified IT platform that supports small molecule, large molecule and novel modality discovery workflows, including registration.”
Today, companies typically use separate filing systems, one for small molecules and another for large molecules. For multimodal discovery, separate registration becomes problematic. A unified registration system solves this by enabling researchers from different departments, such as chemistry and molecular biology, to collaborate on new methods seamlessly, manage all data in one place, have a regulatory compliance system, and collaborate with a single source of truth.
The basis of the Sapio platform is a unified materials management system that does not distinguish between small molecule, large molecule, or multimodal entities — rather, they are all collected and managed as molecular materials with attributes that capture the unique characteristics of each type of entity.
Uniquely, Sapio also links its sample management to registered entities for seamless data visualizations and traceability. As a result, chemists and biologists can collaborate on a single, unified drug discovery platform that combines Sapio LIMS™, Sapio ELN™ and Rotten Jarvis™ for the integration and harmonization of collective scientific data across the laboratory informatics enterprise.
New biotech companies will want to adopt it Sapio Platform now to address breakthrough drug discovery opportunities in new methods and position themselves for rapid discovery and insights from day one.
Biopharma incumbents will want to reassess the limitations and risks of currently developing separate chemistry- and biology-centric informatics and evaluate the benefits and advantages of a single lab informatics platform from Sapio to optimize multimodal drug discovery peak.
